Optimizing a fully automated and closed system process for red blood cell reduction of human bone marrow products

Abstract

Background aimsHematopoietic stem cell transplantation using bone marrow as the graft source is a common treatment for hematopoietic malignancies and disorders. For allogeneic transplants, processing of bone marrow requires the depletion of ABO-mismatched red blood cells (RBCs) to avoid transfusion reactions. Here the authors tested the use of an automated closed system for depleting RBCs from bone marrow and compared the results to a semi-automated platform that is more commonly used in transplant centers today. The authors found that fully automated processing using the Sepax instrument (Cytiva, Marlborough, MA, USA) resulted in depletion of RBCs and total mononuclear cell recovery that were comparable to that achieved with the COBE 2991 (Terumo BCT, Lakewood, CO, USA) semi-automated process. MethodsThe authors optimized the fully automated and closed Sepax SmartRedux (Cytiva) protocol. Three reduction folds (10×, 12× and 15×) were tested on the Sepax. Each run was compared with the standard processing performed in the authors’ center on the COBE 2991. Given that bone marrow is difficult to acquire for these purposes, the authors opted to create a surrogate that is more easily obtainable, which consisted of cryopreserved peripheral blood stem cells that were thawed and mixed with RBCs and supplemented with Plasma-Lyte A (Baxter, Deerfield, IL, USA) and 4% human serum albumin (Baxalta, Westlake Village, CA, USA). This “bone marrow-like” product was split into two starting products of approximately 600 mL, and these were loaded onto the COBE and Sepax for direct comparison testing. Samples were taken from the final products for cell counts and flow cytometry. The authors also tested a 10× Sepax reduction using human bone marrow supplemented with human liquid plasma and RBCs. ResultsRBC reduction increased as the Sepax reduction rate increased, with an average of 86.06% (range of 70.85–96.39%) in the 10×, 98.80% (range of 98.1–99.5%) in the 12× and 98.89% (range of 98.80–98.89%) in the 15×. The reduction rate on the COBE ranged an average of 69.0–93.15%. However, white blood cell (WBC) recovery decreased as the Sepax reduction rate increased, with an average of 47.65% (range of 38.9–62.35%) in the 10×, 14.56% (range of 14.34–14.78%) in the 12× and 27.97% (range of 24.7–31.23%) in the 15×. COBE WBC recovery ranged an average of 53.17–76.12%. Testing a supplemented human bone marrow sample using a 10× Sepax reduction resulted in an average RBC reduction of 84.22% (range of 84.0–84.36%) and WBC recovery of 43.37% (range of 37.48–49.26%). Flow cytometry analysis also showed that 10× Sepax reduction resulted in higher purity and better recovery of CD34+, CD3+ and CD19+ cells compared with 12× and 15× reduction. Therefore, a 10× reduction rate was selected for the Sepax process. ConclusionsThe fully automated and closed SmartRedux program on the Sepax was shown to be effective at reducing RBCs from “bone marrow-like” products and a supplemented bone marrow product using a 10× reduction rate.